Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03564379 · ClinicalTrials.gov registry record · Phase 1

A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants

A Phase 1 study of Healthy, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03564379 is a Phase 1 study of Healthy that has completed, run by Janssen Research & Development. The registered enrollment target is 12 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03564379, a Phase 1 study of Healthy, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG JNJ-42165279

Study Locations (1)

California

  • WCCT Global, LLC - Cypress

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2018-06-12
Est. Completion 2018-08-13
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

What the Registry Record Tells You About NCT03564379

The ClinicalTrials.gov registry entry for NCT03564379 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03564379 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03564379 about?

NCT03564379 is a clinical study titled "A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants". The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of JNJ-42165279 in healthy Japanese male participants after single and multiple oral dose administration.

What is the current status of trial NCT03564379?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-06-12. Estimated completion is 2018-08-13.

What conditions does trial NCT03564379 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03564379?

The interventions under investigation include: Placebo (DRUG), JNJ-42165279 (DRUG).

Who is sponsoring clinical trial NCT03564379?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03564379 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.